Form 4: Quoin Pharmaceuticals Director Joseph Cooper Granted Significant Stock Options

Joseph Patrick Cooper, a Director at Quoin Pharmaceuticals, Ltd., was granted 7,760 share options with an exercise price of $9.07 per American Depositary Share (ADS), vesting over four years.

Summary

• Joseph Patrick Cooper, a Director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted 7,760 share options on May 29, 2025.
• Each share option represents the right to purchase one American Depositary Share (ADS) of Quoin Pharmaceuticals.
• The exercise price for these options is $9.07 per ADS.
• Each ADS represents thirty-five ordinary shares of the Issuer.
• The options vest in four annual installments: 20% on May 29, 2026, 20% on May 29, 2027, 20% on May 29, 2028, and the remaining 40% on May 29, 2029.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Joseph Cooper beneficially owns 7,760 derivative securities (share options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice aimed at aligning incentives, generally viewed as neutral to slightly positive as it ties management's financial success to the company's stock performance. It does not, however, indicate immediate operational or financial results.

Positives

• The grant of stock options to a director aligns their long-term interests with those of shareholders, incentivizing performance that drives stock appreciation.
• The options have a 10-year expiration period, providing a substantial window for the company's stock price to potentially increase above the exercise price.

Negatives

• The value of the options is contingent on the future market price of Quoin Pharmaceuticals' ADSs exceeding the $9.07 exercise price.
• Future exercise of these options could lead to dilution for existing shareholders.

Risks

• The options may expire worthless if the market price of Quoin Pharmaceuticals' ADSs does not rise above the exercise price of $9.07 per ADS by the expiration date.
• The vesting schedule ties the director's compensation to long-term performance, but also means the full benefit is not immediate.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned management incentives for long-term stock appreciation.
• Joseph Cooper (Director): Receives a significant equity-based incentive that directly links his personal financial gain to the company's stock performance over the next decade.

Next Steps

• The granted options will vest annually on May 29, 2026, 2027, 2028, and 2029, as per the vesting schedule.
• Joseph Cooper may exercise the vested options at any time before their expiration on May 29, 2035, subject to the stock price being favorable.

Key Dates

Keywords

Quoin Pharmaceuticals, QNRX, Form 4, SEC Filing, Stock Options, Director Compensation, Equity Grant, American Depositary Shares, ADS, Insider Transaction